Amylyx Pharmaceuticals Inc (AMLX)
R&D Expense Growth
-13.92%
Quarterly · Period ending:
AMLX R&D Expense Growth
Latest reported-13.92%period ending
Latest reported-13.92%period ending
AMLX Quarterly R&D Growth (QoQ) (0.00% → -13.92%)
Latest values, visible window
High-resolution chart · PNG
AMLX r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| -13.9152% | |
| 30.8221% | |
| 6.2956% | |
| -26.6694% | |
| 22.4106% | |
| -3.3767% | |
| 7.793% | |
| -8.2199% | |
| -36.7925% | |
| -18.4931% | |
| 49.5289% | |
| 3.419% | |
| 20.0562% | |
| 6.0448% | |
| -8.433% | |
| 2.7% | |
| 13.0218% | |
| 60.2509% | |
| 4.2091% | |
| 17.6045% | |
| 59.222% | |
| 36.924% | |
| 0% |